Atezolizumab-bevacizumab and Other Immunotherapies: Real-life Experience for Treatment of Hepatocellular Carcinoma
Launched by IRCCS AZIENDA OSPEDALIERO-UNIVERSITARIA DI BOLOGNA · Jan 28, 2025
Trial Information
Current as of June 27, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is looking at how effective and safe different combinations of treatments are for patients with hepatocellular carcinoma (HCC), a serious type of liver cancer. The study will focus on new treatment combinations like atezolizumab-bevacizumab and durvalumab-tremelimumab, especially for patients whose cancer cannot be treated with local procedures. Researchers want to find the best ways to treat advanced liver cancer and identify certain markers that can help predict how well a patient might respond to these treatments. This information will help doctors provide better, personalized care for patients with liver cancer.
To be eligible for this trial, participants should have HCC that cannot be treated with local methods and should be candidates for the frontline systemic treatment with the mentioned immunotherapies. The trial is open to all adults aged 65 to 74. Participants can expect to receive one of the new treatment combinations and contribute to important research that could improve future treatment options for others facing similar challenges. If you're considering joining this trial, it could be a valuable opportunity to help shape the future of liver cancer treatment.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Hepatocellular carcinoma not amenable to locoregional procedures
- • Candidate to frontline systemic treatment with atezolizumab-bevacizumab or other immunotherapies
- Exclusion Criteria:
- • Concurrent treatment with other antineoplastic agents
- • Other active neoplasia
About Irccs Azienda Ospedaliero Universitaria Di Bologna
IRCCS Azienda Ospedaliero-Universitaria di Bologna is a prestigious research and healthcare institution in Italy, renowned for its commitment to advancing medical science and patient care through innovative clinical research. As an IRCCS (Istituto di Ricovero e Cura a Carattere Scientifico), it integrates clinical practice with scientific research, facilitating the translation of laboratory findings into effective treatment strategies. The institution fosters a multidisciplinary approach, collaborating with various experts to conduct high-quality clinical trials aimed at improving health outcomes across a wide range of medical fields. With a strong emphasis on ethical standards and patient welfare, IRCCS Azienda Ospedaliero-Universitaria di Bologna plays a vital role in shaping the future of medicine through rigorous scientific inquiry and patient-centered care.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Bologna, , Italy
Torrette, An, Italy
Castellana Grotte, Ba, Italy
Bologna, Bo, Italy
Bologna, Bo, Italy
Bologna, Bo, Italy
Catania, Ct, Italy
Foggia, Fg, Italy
Foggia, Fg, Italy
Firenze, Fi, Italy
Modena, Missouri, Italy
Milano, Mi, Italy
Milano, Mi, Italy
Rozzano, Mi, Italy
Palermo, Pa, Italy
Padova, Pd, Italy
Pisa, Pi, Italy
Faenza, Ra, Italy
Reggio Emilia, Re, Italy
Roma, Rm, Italy
Udine, Ud, Italy
Verona, Vr, Italy
Napoli, , Italy
Novara, , Italy
Patients applied
Trial Officials
Francesco Tovoli, MD
Principal Investigator
IRCCS Azienda Ospedaliero-Universitaria di Bologna
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported